In a challenging year for In8bio Inc, the biotechnology firm’s stock has hit a 52-week low, trading at just $0.21. According to InvestingPro data, the company maintains a current ratio of 4.08 and holds more cash than debt, despite its small market capitalization of $18 million. This latest price point underscores a significant downturn for the company, with the stock experiencing a precipitous 1-year change, plummeting by -82.24%. Investors have watched with concern as INAB shares have steadily declined, reaching this low threshold and reflecting broader market trends that have impacted the biotech sector. The 52-week low serves as a stark indicator of the hurdles In8bio Inc faces as it strives to regain its footing in a competitive and rapidly evolving industry landscape. Despite current challenges, analyst price targets range from $1.20 to $7.50, suggesting potential recovery opportunities. InvestingPro subscribers can access 8 additional key insights about INAB’s financial health and future prospects.
In other recent news, IN8bio Inc. reported promising Phase 1 trial results for its INB-100 therapy, which showed a 100% relapse-free survival rate at a median follow-up of 20.1 months in patients with acute myeloid leukemia (AML). The trial results also demonstrated a one-year progression-free survival rate of 90.9% and an overall survival rate of 100%, outperforming historical controls. This development has led Jones Trading to upgrade IN8bio’s stock rating from Hold to Buy, setting a new price target of $1.20. Additionally, H.C. Wainwright maintained its Buy rating for IN8bio, though it lowered the price target from $8.00 to $6.00, citing the dilutive effect of a recent capital raise.
In leadership changes, IN8bio announced the resignation of Travis Whitfill from its Board of Directors, effective May 9, 2025, with no successor named yet. The company clarified that Whitfill’s resignation was not due to disagreements with the company’s operations or policies. Meanwhile, IN8bio continues to advance its clinical programs, including the INB-619 product aimed at treating cancers and autoimmune diseases, with plans to present preclinical data in 2025. These developments reflect ongoing progress in IN8bio’s efforts to enhance its therapeutic offerings and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.